Review



belatacept  (Florman Family Foundation)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Florman Family Foundation belatacept
    Summary of findings for the main comparison
    Belatacept, supplied by Florman Family Foundation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/function+from+the+phased+array+system+toolbox/belatacept/pmc06486198-1051-31-4
    Average 90 stars, based on 1 article reviews
    belatacept - by Bioz Stars, 2026-11
    90/100 stars

    Images

    1) Product Images from "Belatacept for kidney transplant recipients"

    Article Title: Belatacept for kidney transplant recipients

    Journal: The Cochrane Database of Systematic Reviews

    doi: 10.1002/14651858.CD010699.pub2

    Summary of findings for the main comparison
    Figure Legend Snippet: Summary of findings for the main comparison

    Techniques Used: Comparison, Virus, Control

    Comparison 1 Any dosage belatacept versus calcineurin inhibitor (CNI), Outcome 1 Recipient and kidney survival.
    Figure Legend Snippet: Comparison 1 Any dosage belatacept versus calcineurin inhibitor (CNI), Outcome 1 Recipient and kidney survival.

    Techniques Used: Comparison

    Comparison 1 Any dosage belatacept versus calcineurin inhibitor (CNI), Outcome 2 Surviving with a functioning transplant.
    Figure Legend Snippet: Comparison 1 Any dosage belatacept versus calcineurin inhibitor (CNI), Outcome 2 Surviving with a functioning transplant.

    Techniques Used: Comparison

    Comparison 1 Any dosage belatacept versus calcineurin inhibitor (CNI), Outcome 3 Acute rejection and chronic kidney scarring.
    Figure Legend Snippet: Comparison 1 Any dosage belatacept versus calcineurin inhibitor (CNI), Outcome 3 Acute rejection and chronic kidney scarring.

    Techniques Used: Comparison

    Comparison 1 Any dosage belatacept versus calcineurin inhibitor (CNI), Outcome 4 Kidney function, blood pressure and lipids.
    Figure Legend Snippet: Comparison 1 Any dosage belatacept versus calcineurin inhibitor (CNI), Outcome 4 Kidney function, blood pressure and lipids.

    Techniques Used: Comparison

    Comparison 1 Any dosage belatacept versus calcineurin inhibitor (CNI), Outcome 5 Malignancy.
    Figure Legend Snippet: Comparison 1 Any dosage belatacept versus calcineurin inhibitor (CNI), Outcome 5 Malignancy.

    Techniques Used: Comparison

    Comparison 1 Any dosage belatacept versus calcineurin inhibitor (CNI), Outcome 6 Infections.
    Figure Legend Snippet: Comparison 1 Any dosage belatacept versus calcineurin inhibitor (CNI), Outcome 6 Infections.

    Techniques Used: Comparison

    Comparison 1 Any dosage belatacept versus calcineurin inhibitor (CNI), Outcome 7 Diabetes and use of blood pressure medicines.
    Figure Legend Snippet: Comparison 1 Any dosage belatacept versus calcineurin inhibitor (CNI), Outcome 7 Diabetes and use of blood pressure medicines.

    Techniques Used: Comparison

    Comparison 2 High versus low dosage belatacept, Outcome 1 Recipient and kidney survival.
    Figure Legend Snippet: Comparison 2 High versus low dosage belatacept, Outcome 1 Recipient and kidney survival.

    Techniques Used: Comparison

    Comparison 2 High versus low dosage belatacept, Outcome 2 Surviving with a functioning transplant.
    Figure Legend Snippet: Comparison 2 High versus low dosage belatacept, Outcome 2 Surviving with a functioning transplant.

    Techniques Used: Comparison

    Comparison 2 High versus low dosage belatacept, Outcome 3 Acute rejection and chronic kidney scarring.
    Figure Legend Snippet: Comparison 2 High versus low dosage belatacept, Outcome 3 Acute rejection and chronic kidney scarring.

    Techniques Used: Comparison

    Comparison 2 High versus low dosage belatacept, Outcome 4 Kidney function, blood pressure and lipids.
    Figure Legend Snippet: Comparison 2 High versus low dosage belatacept, Outcome 4 Kidney function, blood pressure and lipids.

    Techniques Used: Comparison

    Comparison 2 High versus low dosage belatacept, Outcome 5 Malignancy.
    Figure Legend Snippet: Comparison 2 High versus low dosage belatacept, Outcome 5 Malignancy.

    Techniques Used: Comparison

    Comparison 2 High versus low dosage belatacept, Outcome 6 Infections.
    Figure Legend Snippet: Comparison 2 High versus low dosage belatacept, Outcome 6 Infections.

    Techniques Used: Comparison

    Comparison 2 High versus low dosage belatacept, Outcome 7 Diabetes and use of blood pressure medicines.
    Figure Legend Snippet: Comparison 2 High versus low dosage belatacept, Outcome 7 Diabetes and use of blood pressure medicines.

    Techniques Used: Comparison


    Figure Legend Snippet:

    Techniques Used: Transplantation Assay, Clinical Proteomics

    Any dosage belatacept versus calcineurin inhibitor (CNI)
    Figure Legend Snippet: Any dosage belatacept versus calcineurin inhibitor (CNI)

    Techniques Used: Infection

    Related Articles

    other:

    Article Title: Belatacept for kidney transplant recipients
    Article Snippet: [EMBASE: 71545051] Muehlbacher F, Florman S, Medina-Pestana J, Rial M, Rostaing L, Grinyo J, et al.Long-term exposure to belatacept in recipients of extended criteria donor kidneys [abstract no: O066].

    Article Title: Belatacept als „standard of care“ für die Nierentransplantation?
    Article Snippet: Hintergrund.Trotz einerdeutlichenVerbesserung der immunsuppressiven Therapie über die letzten Jahrzehnte und dem zweifelsfreien Vorteil gegenüber der Dialyse ist die Entwicklung der Langzeitverläufe nach Nierentransplantation in Bezug auf Transplantatund Patientenüberleben nicht zufriedenstellend [4].. Dies liegt unter anderem an der fortbestehenden kardiovaskulären Mortalität der Empfänger, der Nephrotoxizität der meist verwendeten Calcineurininhibitoren (CNI) und der häufigen antikörpervermittelten Rejektion [6].. Nachdem über 10 Jahre keine Zulassung neuerMedikamente für die Nierentransplantation erreicht werden konnte, wurde 2011 der Kostimulationsblocker Belatacept in Europa und den USA auf der Basis zweier 3-Jahres-Studien zugelassen [7, 10].

    Transplantation Assay:

    Article Title: Pancreatic islets of transgenic LEA29Y animals for treating diabetes
    Article Snippet: .. Transplantation 80:555-563, 2005 Durrbach A, Pestana J M, Pearson T, Vincenti F, Garcia V D, Campistol J, Rial Mdel C, Florman S, Block A, Di Russo G, Xing J, Garg P, Grinyo J: A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). ..

    Article Title: Belatacept for kidney transplant recipients
    Article Snippet: .. [EMBASE: 70537445] Florman S, Becker T, Bresnahan B, Chevaile-Ramos A, DeCarvalho D, Muehlbacher F, et al.Three-year outcomes by donor type in phase III studies of belatacept vs cyclosporine in kidney transplantation (BENEFIT & BENEFIT-EXT) [abstract no: 229]. ..

    Article Title: Belatacept for kidney transplant recipients
    Article Snippet: .. Florman S, Becker T, Bresnahan B, Chevaile-Ramos A, Carvalho D, Muehlbacher F, et al.Three year outcomes by donor type in phase III studies of belatacept vs cyclosporine in kidney transplantation (BENEFIT and BENEFIT-EXT) [abstract no: P145]. ..

    Blocking Assay:

    Article Title: Pancreatic islets of transgenic LEA29Y animals for treating diabetes
    Article Snippet: .. Transplantation 80:555-563, 2005 Durrbach A, Pestana J M, Pearson T, Vincenti F, Garcia V D, Campistol J, Rial Mdel C, Florman S, Block A, Di Russo G, Xing J, Garg P, Grinyo J: A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). ..



    Similar Products

    function from the phased array system toolbox  (MathWorks Inc)
    90
    MathWorks Inc function from the phased array system toolbox
    Function From The Phased Array System Toolbox, supplied by MathWorks Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/function+from+the+phased+array+system+toolbox/pmc10675705-106-15-10
    Average 90 stars, based on 1 article reviews
    function from the phased array system toolbox - by Bioz Stars, 2026-11
    90/100 stars
    		  Buy from Supplier

    Image Search Results